Lykos Therapeutics details how it is addressing questions raised by FDA advisors during a June 4 advisory meeting and how it will apply these insights to its Risk Evaluation and Mitigation Strategy.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics considers a Risk Evaluation and Mitigation Strategy for MDMA-assisted therapy, both supporters and detractors of MDMA-AT make their case for whether the treatment is safe for patients.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness